Japan Antifungal Drugs Market Size & Outlook, 2023-2030
Japan antifungal drugs market, 2018-2030 (US$M)
Related Markets
Japan antifungal drugs market highlights
- The Japan antifungal drugs market generated a revenue of USD 1,062.7 million in 2023 and is expected to reach USD 1,470.8 million by 2030.
- The Japan market is expected to grow at a CAGR of 4.8% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 1,062.7 million |
| Market revenue in 2030 | USD 1,470.8 million |
| Growth rate | 4.8% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Japan accounted for 6.7% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,381.0 million by 2030.
Azoles was the largest segment with a revenue share of 47.54% in 2023. Horizon Databook has segmented the Japan antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Key players are engaged in product approval and launches in the country. For instance, in 2018, Eisai Co., Ltd. and Sato Pharmaceutical Co., Ltd. announced the launch of NAILIN Capsules in the country.
Similarly, in January 2020, Astellas announced the approval of its antifungal drug micafungin (Mycamine) for the treatment of newborns (below 4 months of age) with candidemia, acute disseminated candidiasis, or candida peritonitis.
Japan’s Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical and Medical Device Agency (PMDA) govern the drug application, clinical trials, & approval of new drugs in the country. The PMDA recommends and forwards applications to MHLW for approval.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan antifungal drugs market size, by drug class, 2018-2030 (US$M)
Japan Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
